临床试验/NCT05482971

NCT05482971进行中（未招募）2 期

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Essential Thrombocythemia

PharmaEssentia34 个研究点分布在 2 个国家目标入组 91 人开始时间: 2022年9月29日最近更新: 2025年8月13日

适应症

干预措施

试验速览

阶段: 2 期
状态: 进行中（未招募）
发起方
入组人数: 91
试验地点: 34
主要终点: To assess efficacy of ropeginterferon alfa-2b-njft (P1101) in adult USA/Canadian patients with ET

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验相关资讯

研究概览

简要总结

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in Adult Patients with Essential Thrombocythemia

详细描述

PharmaEssentia is developing a pegylated (PEG) IFN-α product, P1101, for the treatment of Essential Thrombocythemia (ET) as lack of disease modifying therapies in essential ET constitutes a serious issue in modern hematology.

Ropeginterferon alfa-2b-njft (P1101) may represent an effective, well-tolerated treatment with the ability to provide a deeper response and superior control of important blood parameters with the potential to alter the course of the disease and prevent progression to post-ET myelofibrosis (MF) and/or secondary acute myeloid leukemia (sAML). Ropeginterferon alfa-2b-njft (P1101) is currently being evaluated in comparison to ANA in the ongoing global Phase 3 clinical study, SURPASS ET.

Enrolled patients will receive P1101 over 13 months followed by an extension period.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Male and female subjects ≥18 years old.
•Subjects diagnosed with ET according to the World Health Organization (WHO) 2016 criteria.
•Subjects that are cytoreductive treatment-naïve, or pre-exposed to HU and/or ANA, as specified below (according to Investigator's judgment and documented in the patient's medical record):
•a. Cytoreductive-naïve patients must be in need of cytoreductive treatment, defined as having at least one of the following:
•i. Progressive leukocytosis and/or thrombocytosis
•ii. Disease-related symptoms (i.e., pruritus, night sweats, fatigue)
•iii. Vasomotor/microvascular disturbances, not responsive to aspirin (including headache, chest pain or erythromelalgia, etc.)
•iv. High-risk (history of thrombosis at any age; or age >60 years with JAK2 mutation)
•b. Patients previously exposed to HU will be classified as either:
•i. Documented formal HU resistance or intolerance
•ii. HU stopped without documented formal resistance/intolerance due to insufficient blood count control or toxicity. The last HU dose must be >7 days prior the first dose of P
•Adequate hepatic function defined as bilirubin ≤1.5 × upper limit normal (ULN), prothrombin time (PT) (international normalized ratio, [INR]) ≤1.5 x ULN, albumin >3.5 g/dL, alanine aminotransferase (ALT) ≤2.0 x ULN, aspartate aminotransferase ≤2.0 x ULN at screening.
•Creatinine clearance ≥40 mL/min (by Cockcroft-Gault equation).
•Males and females of childbearing potential, as well as all women <2 years after the onset of menopause, must agree to use an acceptable form of birth control until 60 days following the last dose of the study drug, and females must agree to not breastfeed during the study.
•Written informed consent obtained from the subject and ability for the subject to comply with the requirements of the study.
•Platelet count >450 × 109/L at screening
•Both ANA-naïve and ANA-pretreated subjects are eligible for the study, regardless of the reason to terminate ANA use

排除标准

•Any subject requiring a legally authorized representative
•Subjects who stopped prior interferon alfa therapy due to low efficacy or poor tolerability
•Any contraindications or hypersensitivity to IFN-α and/or its excipients
•Co-morbidity with severe or serious condition that, in the Investigator's opinion, would jeopardize the safety of the subject or their compliance with the protocol, including significant cardiac disease (including New York Heart Association Class III-IV congestive heart failure and clinically significant arrhythmias) and pulmonary hypertension
•History of major organ transplantation
•Pregnant or lactating females
•Subjects with any significant medical conditions that, in the opinion of the Investigator, would compromise the results of the study or may impair compliance with the requirements of the protocol, including but not limited to:
•Documented autoimmune disease at screening or in the history (e.g., thyroid dysfunction, hepatitis, idiopathic thrombocytopenic purpura, scleroderma, psoriasis, or any arthritis of autoimmune origin)
•Clinically relevant pulmonary infiltrates, pneumonia, and pneumonitis at screening that, in the Investigator's opinion, would jeopardize the safety of the subject or their compliance with the protocol
•Infections with systemic manifestations (e.g., bacterial, fungal, or human immunodeficiency virus [HIV], except hepatitis B [HBV] and/or hepatitis C [HCV],at screening)
•Evidence of severe retinopathy (e.g., cytomegalovirus retinitis [CMV], macular degeneration) or clinically relevant ophthalmological disorder (due to diabetes mellitus or hypertension)
•History or presence of clinically relevant depression
•Previous suicide attempts or at any risk of suicide at screening, in the judgment of the Investigator
•History or presence of clinically significant neurologic diseases
•History of any malignancy within 5 years (except adequately treated nonmelanoma skin cancer, prostate cancer status post resection with an undetectable prostate-specific antigen [PSA], curative treated in-situ cancer of the cervix, ductal carcinoma in-situ [DCIS] of the breast, Stage 1 Grade 1 endometrial carcinoma, or other solid tumors including lymphomas [without bone marrow involvement] curatively treated with no evidence of disease for ≥2 years prior to study)
•History of alcohol or drug abuse within the last year
•History or evidence of any other MPN
•Use of any investigational drug <4 weeks prior to the first dose of study drug or not recovered from effects of prior administration of any investigational agent
•Presence of more than one driver mutation (e.g., V617F JAK2 and CALR, CALR and MPL, V617F JAK2 and MPL)
•Prior use of JAK inhibitors

研究组 & 干预措施

Ropeginterferon alfa-2b (P1101)

Experimental

Pre-filled Syringe, Q2W, SC injection

干预措施: Ropeginterferon alfa-2b-njft (P1101) (Drug)

结局指标

主要结局

To assess efficacy of ropeginterferon alfa-2b-njft (P1101) in adult USA/Canadian patients with ET

时间窗: 12 months

Efficacy will be based on peripheral blood count remission as defined by hematocrit (HCT) \<45%, white blood cell (WBC) count ≤10 × 109/L, and platelets (PLT) ≤ 400 × 109/L in at least 80% of bi-weekly measurements for a consecutive 32-wek period during the 52-week core study treatment period.

次要结局

未报告次要终点

研究者

发起方

PharmaEssentia

申办方类型

Industry

责任方

Sponsor

研究点 (34)

Loading locations...

相似试验

尚未招募

1 期

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast CancerMetastatic Triple-negative Breast Cancer

NCT05746728Huihua Xiong45

已完成

3 期

A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar LinesModerate to Severe Glabellar Lines

NCT06583486Chongqing Claruvis Pharmaceutical Co., Ltd.488

进行中（未招募）

2 期

A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe ADAtopic Dermatitis

NCT05905133Suzhou Connect Biopharmaceuticals, Ltd.360

已完成

不适用

Prospective, Multicentre Study to Evaluate the Thrombectomy System for Stroke: iNedit, iNdeep and iNterceptAcute Ischemic Stroke

NCT05893719iVascular S.L.U.175

Unknown

3 期

A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin ResistanceInsulin Resistance - Type AInsulin Resistance - Type BLipoatrophic Diabetes MellitusInsulin Resistance Syndrome

NCT04018365Kobe University8